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Abstract  
In October 2012, a maternal pertussis vaccination programme was implemented in 
England following an increased incidence and mortality in infants. We evaluated the 
cost-effectiveness of the programme by comparing pertussis-related infant 
hospitalisations and deaths in 2012-2017 with non-vaccination scenarios. Despite 
considerable uncertainties, findings support the cost-effectiveness of the 
programme. 
 
Keywords. maternal pertussis vaccination; Whooping Cough; Pertussis Vaccine; 
Economic Evaluation; Post-implementation 
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Introduction 
Following sharply increased pertussis-related incidence and mortality in infants, a 
pertussis vaccination programme for pregnant women was implemented in England 
in October 2012 as an outbreak control measure. The programme has been highly 
effective in England in protecting infants in the first two months of life [1]. Maternal 
vaccination has the advantage of conferring passive protection to the foetus via 
transplacental transfer of antibodies and of reducing maternal transmission to 
infants until they can be actively protected via primary immunisations [2]. 
In 2014, the Joint Committee on Vaccination and Immunisation (JCVI) agreed to 
continue the maternal programme for a further five years, with a decision to be 
made in 2019 about whether to maintain it as a routine programme [1]. This post-
implementation evaluation hence reports on the 6-year impact and cost-
effectiveness of the existing maternal vaccination programme (as compared to non-
vaccination scenarios), using high-quality enhanced surveillance data to inform 
policy making. 
Methods 
Our cost-effectiveness analysis focused on pertussis-related hospitalisations and 
deaths in infants aged 0-2 months (i.e., <3 months) in England between 2012 and 
2017. 
For the maternal vaccination programme, we used the Hospital Episode Statistics 
(HES) database to observe the number of hospitalisations (Finished Admission 
ƉŝƐŽĚĞƐ ?ŽĨƉĞƌƚƵƐƐŝƐ ? ?tŚŽŽƉŝŶŐĐŽƵŐŚ ? ?/-10 code A37) in any diagnostic field 
for the period 10/2012-12/2017. For the non-vaccination scenarios, we considered 
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two approaches to estimate the number of infant hospitalisations potentially 
prevented through the maternal programme: 
1. First, we applied the annual change in the number of hospitalisations 
(in age groups other than <3 months) after 2011 to infants aged <3 
months (Supplementary Table 1). We considered the age groups of 3-
11 months (i.e. up to 364 days; scenario S1), 6-11 months (S2), 1-2 
years (S3), and 5-9 years (S4). 
2. Second, we back-estimated the annual number of hospitalisations 
potentially seen without the maternal programme based on the 
observed number of hospitalisations in inpatients aged <3 months, the 
estimated vaccine effectiveness (VE) in infants (0.91) [1], and the 
annual(ised) vaccine coverage based on two data sources (ImmForm, 
S5; CPRD, S6): 
 
EsWLPDWHGLQSDWLHQWV 2EVHUYHGLQSDWLHQWVí9(FRYHUDJH 
 
ImmForm is a routinely collected extraction of records in >90% of 
general practitioner (GP) practices in England; CPRD (Clinical 
Practice Research Datalink) is a representative sentinel dataset of 
approximately 5% of GP practices in England. Following a change in 
how the data were extracted from ImmForm in April 2016, the 
reported coverage increased and aligned more closely to the estimates 
from CPRD, suggesting that ImmForm had previously underestimated 
coverage [1]. GP datasets were used as the maternal programme was 
delivered almost exclusively in primary care [3]. 
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In terms of mortality, with the maternal vaccination programme in place, 17 deaths 
occurred due to pertussis in infants aged <3 months born between October 2012 
and December 2017 [1]. Of these, two were to mothers who were vaccinated but 
too near to birth to confer passive protection (15 were to unvaccinated mothers). 
For all non-vaccination scenarios (i.e. S1-S6), the number of infant deaths was 
extrapolated based on the estimated number of hospitalisations and the case-
fatality risk (CFR) for hospitalised infants aged <3 months in England from before the 
vaccination programme was introduced (16/513=0.0312 between October 2011 and 
September 2012 [4]). We conservatively assumed the infant CFR without the 
maternal vaccination programme would not have returned to pre-resurgence levels 
given the continued and exclusive use of acellular pertussis vaccines in England since 
2004, which are thought to have contributed to the resurgence of severe cases and 
deaths in infants and the elevated disease activity seen across all ages ever since 
2012 due to diminished indirect protection from infection [1, 5]. In a scenario 
analysis, however, we explored the return of the CFR to pre-resurgence levels even 
without having adopted the maternal programme. 
For both the vaccination programme and the non-vaccination scenarios, we 
assumed infants lost 0.10070 quality-adjusted life years (QALYs) per hospitalisation 
[4], and 25.6 vs 42.6 QALYs per fatality when discounting at 3.5% vs 1.5% (which 
were estimated from official statistics of life expectancy at birth in England in 2012-
2017 and the estimated population norms of the quality of life in England by sex and 
age [6]). 
We considered the costs of hospitalisations and the vaccination programme to the 
National Health Service (NHS) in England. The hospitalisation costs were based on 
NHS reference costs for 2012/2013 to 2017/2018 (Supplementary Table 2). The data 
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were obtained for 2006-2017 from HES and the Paediatric Intensive Care Audit 
Network (PICANet), and we used the data pre-dating the maternal vaccination 
programme for extrapolation of the non-vaccination scenarios in 2012-2017 
(Supplementary Table 3). 
For the costs of vaccination, we considered the published indicative list price of the 
vaccine and the annual service payment for administering the vaccine [7, 8]. The unit 
cost per patient was conservatively multiplied with the annual coverage rates of the 
higher estimates of CPRD [1], and the annual number of officially recorded 
maternities in England in 2012-2017 [9]. 
Since this was a post-implementation economic evaluation, we discounted all QALYs 
and costs back to the base year of the immunisation programme introduction in 
2012 [10]. 
Results 
With the maternal vaccination programme, the annually observed number of 
hospitalisations of pertussis inpatients aged <3 months was a mean of 207 in 2013-
2017 (231 when annualising over 10/2012-2017; Figure 1A), while the CFR was a 
mean of 17/1,211=0.014 between October 2012 and December 2017. 
For the non-vaccination scenarios, the estimated absolute numbers of 
hospitalisations differed each year, but the trend over time in terms of peaks and 
troughs was similar across non-vaccination scenarios (S1-S6), and between the non-
vaccination scenarios and the observed number of hospitalisations (Figure 1A). The 
similar trends suggest no sudden change had the programme not been adopted, 
providing some reassurance for the validity of the back-estimated scenarios S5-S6. 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/c
id
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/c
id
/c
ia
a
1
6
5
/5
7
5
4
4
9
0
 b
y
 U
n
iv
e
rs
ity
 o
f L
e
e
d
s
 - L
ib
ra
ria
n
 u
s
e
r o
n
 1
3
 M
a
rc
h
 2
0
2
0
 7 
Depending on the non-vaccination scenario, the maternal vaccination programme 
was estimated to have prevented 1,400-4,300 infant hospitalisations in 2012-2017, 
at net economic costs of £50-£58 million (discounted at 3.5%) or £53-£62 million 
(discounted at 1.5%; Figure 1B). These costs reflect both decreased expenditures on 
infant hospitalisations and additional expenditures on vaccination (Figure 1B). 
In terms of fatalities and QALYs, the maternal vaccination is estimated to have 
prevented 82-170 infant deaths and 2,100-4,500 or 3,500-7,500 infant QALY losses 
(discounted at 3.5% or 1.5%, respectively; Figure 1C). Assuming the CFR to have 
returned to pre-resurgence levels even without maternal immunisation, the 
programme would have prevented an estimated 41-96 infant deaths and 1,100-
2,700 or 1,800-4,400 infant QALY losses (discounted at 3.5% or 1.5%, respectively). 
Overall, the incremental costs-per-QALY gained from the programme vs. the non-
vaccination scenarios ranged between £11,000-£28,200/QALY and £7,000-
£17,700/QALY when discounting at 3.5% and 1.5%, respectively (Figure 1D). The 
changes seen in the incremental cost-effectiveness ratios over time reflect the 
cyclical nature of pertussis (Figure 1A), with peaks occurring every 3-4 years in 
England [1]. These values increased to £18,400-£52,000/QALY and £12,100-
£33,500/QALY when assuming the CFR would have returned to pre-resurgence 
levels even without having adopted the maternal programme (Supplementary Figure 
1). 
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Discussion 
In England, introducing the maternal pertussis vaccination programme appears to 
have been cost-effective in reducing the annual number of infant hospitalisations 
and deaths between 2012 and 2017 up to the published list prices of the vaccines, 
despite considerable uncertainties regarding the outcomes. 
Our study focused on the most important cost factors from the NHS perspective, 
while ignoring the direct protection for vaccinated pregnant women and the 
resultant cocooning effect that may help reduce infection even after infant 
vaccination begins [1]. Our focus on infant hospitalisations seems justified given the 
high proportion of pertussis-confirmed infants aged <3 months seen in hospital in 
England (>90%) [11]. 
For the non-vaccination scenarios S1-S4, scenario S4 (ages 5-9 years) needs to be 
interpreted with caution given the low absolute numbers of hospitalisations and the 
resulting larger relative annual changes. Moreover, some of the younger infants 
within scenario S1 (ages 3-11 month) may still experience some residual protection 
from maternal immunisation (possibly a cocooning effect), while those aged 6-11 
months (scenario S2) may experience diminished protection after primary 
vaccination due to blunting following maternal vaccination (despite no clinically 
significant blunting having been demonstrated in England [1]). Furthermore, the 
back-calculated scenarios S5-S6 may lack precision as they assumed no socio-
economic gradient for both disease risk and coverage [12]; an exploratory scenario 
analysis by region resulted in slightly higher ICERs (Supplementary Table 4). 
Our analysis did not account for long-term disability in PICU survivors [13], explore 
additional parameter uncertainty, had a retrospective 6-year timeframe only, and 
did not explicitly model transmission dynamics [5]. Contrasting two discount rates 
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also helps illustrating their different impact on QALYs lost per infant death. Ongoing 
research explores the impact of implementing the programme routinely. 
In conclusion, despite the considerable uncertainties, our findings support the cost-
effectiveness of the maternal pertussis vaccination programme in England in 2012-
2017 up to the published list prices of the vaccines (which are higher than the 
confidential, and hence unknown, tender prices paid by the NHS). 
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Figure 
Figure 1. Findings of the post-implementation evaluation of the maternal pertussis 
vaccination programme in England, 2012-2017, showing the observed vs. estimated 
number of hospitalisations in infants aged <3 months annually (panel a); the total 
costs of the maternal programme with the observed vs. estimated number of 
hospitalisations without the programme (panel b); the total infant QALY loss under 
the maternal programme with the observed vs. estimated total infant QALY loss 
without the programme (panel c); and the cumulative incremental costs-per-QALY 
gained from the maternal programme vs. the non-vaccination programme scenarios 
(panel d). 
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